Dutta, Debasmita http://orcid.org/0000-0003-0235-4649
Liu, Jiye http://orcid.org/0000-0001-7970-7508
Wen, Kenneth
Kurata, Keiji http://orcid.org/0000-0003-1060-9218
Fulciniti, Mariateresa http://orcid.org/0000-0002-1432-9742
Gulla, Annamaria
Hideshima, Teru
Anderson, Kenneth C. http://orcid.org/0000-0002-6418-0886
Funding for this research was provided by:
the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, and the Riney Family Myeloma Initiative.
Article History
Received: 5 August 2023
Revised: 16 November 2023
Accepted: 21 November 2023
First Online: 11 December 2023
Competing interests
: DD, TH, JL, KW, KK, MF, AG have no competing interests relevant to this work. KCA is an American Cancer Society Clinical Research Professor; an advisor for Pfizer, AstraZeneca, Janssen, and Daewoong; and board member with equity interests in C4 Therapeutics, Oncopep, Dynamic Cell Therapies, NextRNA, Window, and Starton therapeutics.